In 2019, the United Kingdom (UK)’s Medicines and Healthcare Products Regulatory Agency (MHRA) issued advice regarding the potential risk of DKA in patients with T2D treated with a combination of a GLP-1 receptor agonist and insulin. Here, GLP1R is linked to type 2 diabetes mellitus.